Yoshiyuki Miyazawa, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatic Neoplasms | 18 | 2024 | 11215 | 1.530 |
Why?
|
| Phenylthiohydantoin | 4 | 2021 | 195 | 1.050 |
Why?
|
| Simvastatin | 5 | 2024 | 350 | 0.990 |
Why?
|
| Trees | 6 | 2022 | 56 | 0.990 |
Why?
|
| Androgen Antagonists | 7 | 2022 | 1415 | 0.920 |
Why?
|
| Plant Leaves | 7 | 2022 | 143 | 0.870 |
Why?
|
| Photosynthesis | 5 | 2022 | 69 | 0.850 |
Why?
|
| Androgens | 3 | 2024 | 1276 | 0.820 |
Why?
|
| Carbon | 3 | 2024 | 673 | 0.700 |
Why?
|
| Nitriles | 6 | 2023 | 948 | 0.690 |
Why?
|
| Robinia | 1 | 2018 | 1 | 0.650 |
Why?
|
| Droughts | 1 | 2018 | 28 | 0.640 |
Why?
|
| Prostate-Specific Antigen | 5 | 2023 | 2511 | 0.610 |
Why?
|
| Annexins | 1 | 2016 | 37 | 0.570 |
Why?
|
| Water | 3 | 2022 | 1396 | 0.560 |
Why?
|
| Robotics | 1 | 2024 | 880 | 0.550 |
Why?
|
| Japan | 6 | 2024 | 1267 | 0.520 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 5 | 2024 | 3272 | 0.510 |
Why?
|
| Antineoplastic Agents | 6 | 2022 | 13586 | 0.500 |
Why?
|
| Bone Density | 2 | 2018 | 3511 | 0.480 |
Why?
|
| Bone Density Conservation Agents | 2 | 2018 | 779 | 0.450 |
Why?
|
| Bone Remodeling | 1 | 2017 | 581 | 0.450 |
Why?
|
| Varicocele | 3 | 2019 | 78 | 0.420 |
Why?
|
| Oligopeptides | 1 | 2017 | 1188 | 0.400 |
Why?
|
| Gonadotropin-Releasing Hormone | 1 | 2017 | 1158 | 0.380 |
Why?
|
| Seasons | 5 | 2018 | 1504 | 0.370 |
Why?
|
| Benzamides | 4 | 2021 | 1347 | 0.370 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2018 | 1511 | 0.340 |
Why?
|
| Cell Proliferation | 5 | 2023 | 10311 | 0.300 |
Why?
|
| Up-Regulation | 1 | 2016 | 4118 | 0.290 |
Why?
|
| Bone and Bones | 1 | 2018 | 2557 | 0.290 |
Why?
|
| Euphorbiaceae | 1 | 2006 | 1 | 0.290 |
Why?
|
| Carbon Dioxide | 3 | 2022 | 1144 | 0.270 |
Why?
|
| Carcinoma, Transitional Cell | 2 | 2023 | 800 | 0.260 |
Why?
|
| Urinary Bladder Neoplasms | 3 | 2023 | 2246 | 0.260 |
Why?
|
| Prostate | 4 | 2023 | 1782 | 0.260 |
Why?
|
| Bone Neoplasms | 1 | 2018 | 2496 | 0.260 |
Why?
|
| Cell Movement | 2 | 2016 | 5166 | 0.250 |
Why?
|
| Thiohydantoins | 2 | 2021 | 19 | 0.250 |
Why?
|
| Betula | 1 | 2004 | 8 | 0.240 |
Why?
|
| Male | 35 | 2024 | 351420 | 0.220 |
Why?
|
| Abies | 1 | 2022 | 1 | 0.220 |
Why?
|
| Poaceae | 1 | 2022 | 24 | 0.210 |
Why?
|
| Cell Line, Tumor | 8 | 2024 | 16667 | 0.200 |
Why?
|
| Urinary Bladder | 3 | 2023 | 1168 | 0.190 |
Why?
|
| Plant Transpiration | 2 | 2014 | 4 | 0.190 |
Why?
|
| Indocyanine Green | 3 | 2019 | 233 | 0.190 |
Why?
|
| Androgen Receptor Antagonists | 1 | 2021 | 118 | 0.190 |
Why?
|
| Ureter | 1 | 2023 | 375 | 0.180 |
Why?
|
| Spermatic Cord | 1 | 2019 | 24 | 0.170 |
Why?
|
| Camellia | 2 | 2011 | 3 | 0.170 |
Why?
|
| Chromatography, Liquid | 1 | 2023 | 966 | 0.170 |
Why?
|
| Embolism | 1 | 2022 | 405 | 0.160 |
Why?
|
| Prognosis | 6 | 2023 | 29079 | 0.160 |
Why?
|
| Cystectomy | 1 | 2023 | 687 | 0.160 |
Why?
|
| Prostatectomy | 2 | 2024 | 1905 | 0.160 |
Why?
|
| Cefazolin | 1 | 2018 | 91 | 0.150 |
Why?
|
| Stevens-Johnson Syndrome | 1 | 2020 | 235 | 0.150 |
Why?
|
| Humans | 36 | 2024 | 746630 | 0.140 |
Why?
|
| Neoplasm Invasiveness | 4 | 2021 | 3585 | 0.140 |
Why?
|
| Naphthoquinones | 1 | 2017 | 60 | 0.140 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2023 | 1164 | 0.140 |
Why?
|
| Propensity Score | 1 | 2024 | 1848 | 0.140 |
Why?
|
| Urologic Surgical Procedures, Male | 1 | 2016 | 75 | 0.140 |
Why?
|
| Androstenes | 1 | 2018 | 173 | 0.140 |
Why?
|
| Sirolimus | 1 | 2023 | 1532 | 0.140 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2023 | 930 | 0.130 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2017 | 198 | 0.130 |
Why?
|
| Urogenital Surgical Procedures | 1 | 2015 | 35 | 0.130 |
Why?
|
| Autophagy | 1 | 2023 | 1322 | 0.130 |
Why?
|
| Femur Neck | 1 | 2017 | 307 | 0.130 |
Why?
|
| 5-alpha Reductase Inhibitors | 1 | 2017 | 116 | 0.130 |
Why?
|
| Anus, Imperforate | 1 | 2015 | 64 | 0.130 |
Why?
|
| Urinary Tract Infections | 1 | 2021 | 801 | 0.130 |
Why?
|
| Shock, Septic | 1 | 2021 | 765 | 0.120 |
Why?
|
| Angiography | 2 | 2019 | 1597 | 0.120 |
Why?
|
| Adrenal Glands | 1 | 2017 | 556 | 0.120 |
Why?
|
| Pyrazoles | 2 | 2022 | 1990 | 0.120 |
Why?
|
| Rubber | 1 | 2014 | 47 | 0.120 |
Why?
|
| Taxoids | 1 | 2018 | 663 | 0.120 |
Why?
|
| Early Detection of Cancer | 2 | 2019 | 3128 | 0.120 |
Why?
|
| Aged | 12 | 2023 | 164383 | 0.120 |
Why?
|
| Testis | 1 | 2017 | 793 | 0.110 |
Why?
|
| Retrospective Studies | 7 | 2024 | 78313 | 0.110 |
Why?
|
| Arginine | 1 | 2017 | 928 | 0.110 |
Why?
|
| Mice, Nude | 2 | 2017 | 3583 | 0.110 |
Why?
|
| Infertility, Male | 1 | 2016 | 399 | 0.110 |
Why?
|
| Aged, 80 and over | 7 | 2023 | 57586 | 0.110 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2018 | 628 | 0.110 |
Why?
|
| Drug Therapy, Combination | 2 | 2021 | 6463 | 0.110 |
Why?
|
| Prostatic Hyperplasia | 1 | 2017 | 525 | 0.110 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2015 | 378 | 0.110 |
Why?
|
| Lysine | 1 | 2017 | 986 | 0.110 |
Why?
|
| Nitrogen | 2 | 2022 | 349 | 0.110 |
Why?
|
| Testosterone | 1 | 2023 | 2439 | 0.100 |
Why?
|
| Environment | 1 | 2018 | 1115 | 0.100 |
Why?
|
| Quality of Life | 2 | 2024 | 12977 | 0.100 |
Why?
|
| Pharmaceutical Preparations | 1 | 2020 | 1075 | 0.100 |
Why?
|
| Weevils | 1 | 2011 | 3 | 0.100 |
Why?
|
| Combined Modality Therapy | 3 | 2021 | 8521 | 0.100 |
Why?
|
| Mice, Inbred BALB C | 2 | 2017 | 6102 | 0.090 |
Why?
|
| Imidazoles | 1 | 2017 | 1167 | 0.090 |
Why?
|
| Estramustine | 1 | 2010 | 35 | 0.090 |
Why?
|
| Apoptosis | 2 | 2023 | 9447 | 0.090 |
Why?
|
| Fluorescein Angiography | 1 | 2015 | 1019 | 0.090 |
Why?
|
| Climate | 1 | 2011 | 143 | 0.090 |
Why?
|
| Cell Cycle Proteins | 1 | 2021 | 3409 | 0.090 |
Why?
|
| Neoplasm Metastasis | 2 | 2018 | 4823 | 0.090 |
Why?
|
| Prospective Studies | 3 | 2023 | 53253 | 0.090 |
Why?
|
| Bacterial Infections | 1 | 2018 | 1396 | 0.090 |
Why?
|
| Ethinyl Estradiol | 1 | 2010 | 115 | 0.090 |
Why?
|
| Peptide Fragments | 1 | 2021 | 5036 | 0.080 |
Why?
|
| Host-Parasite Interactions | 1 | 2011 | 297 | 0.080 |
Why?
|
| Temperature | 2 | 2006 | 2196 | 0.080 |
Why?
|
| Pyrroles | 1 | 2014 | 1131 | 0.080 |
Why?
|
| Lumbar Vertebrae | 1 | 2017 | 1819 | 0.080 |
Why?
|
| Microsurgery | 3 | 2019 | 776 | 0.070 |
Why?
|
| Osteoporosis | 1 | 2017 | 1581 | 0.070 |
Why?
|
| Metformin | 1 | 2015 | 876 | 0.070 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2015 | 1905 | 0.070 |
Why?
|
| Middle Aged | 11 | 2021 | 214618 | 0.070 |
Why?
|
| Tropical Climate | 1 | 2006 | 35 | 0.070 |
Why?
|
| Ribulosephosphates | 1 | 2006 | 1 | 0.070 |
Why?
|
| Fagaceae | 1 | 2006 | 1 | 0.070 |
Why?
|
| Photinia | 1 | 2006 | 2 | 0.070 |
Why?
|
| Quercus | 1 | 2006 | 6 | 0.070 |
Why?
|
| Ribulose-Bisphosphate Carboxylase | 1 | 2006 | 19 | 0.070 |
Why?
|
| Suicide, Attempted | 1 | 2014 | 1232 | 0.070 |
Why?
|
| Indoles | 1 | 2014 | 1806 | 0.070 |
Why?
|
| Biological Evolution | 1 | 2011 | 1056 | 0.060 |
Why?
|
| Electron Transport | 1 | 2006 | 209 | 0.060 |
Why?
|
| Fractures, Bone | 1 | 2017 | 2010 | 0.060 |
Why?
|
| Calcium | 1 | 2018 | 5656 | 0.060 |
Why?
|
| Drainage | 1 | 2010 | 1143 | 0.060 |
Why?
|
| Plant Shoots | 1 | 2004 | 28 | 0.060 |
Why?
|
| Population Dynamics | 1 | 2006 | 300 | 0.060 |
Why?
|
| Adenocarcinoma | 1 | 2021 | 6300 | 0.060 |
Why?
|
| Colonic Neoplasms | 1 | 2015 | 2504 | 0.060 |
Why?
|
| Rad51 Recombinase | 1 | 2024 | 185 | 0.050 |
Why?
|
| Xylem | 1 | 2022 | 6 | 0.050 |
Why?
|
| Estrogens | 1 | 2010 | 1523 | 0.050 |
Why?
|
| Neoplasm Staging | 1 | 2018 | 11078 | 0.050 |
Why?
|
| Retroperitoneal Space | 1 | 2023 | 173 | 0.050 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2017 | 8356 | 0.050 |
Why?
|
| Castration | 1 | 2022 | 153 | 0.050 |
Why?
|
| Disease Progression | 1 | 2019 | 13317 | 0.050 |
Why?
|
| Crops, Agricultural | 1 | 2022 | 36 | 0.050 |
Why?
|
| Sunlight | 1 | 2004 | 333 | 0.050 |
Why?
|
| Freezing | 1 | 2022 | 299 | 0.050 |
Why?
|
| Practice Guidelines as Topic | 1 | 2019 | 7280 | 0.050 |
Why?
|
| Receptors, Fibroblast Growth Factor | 1 | 2022 | 179 | 0.050 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2017 | 5166 | 0.050 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2017 | 3173 | 0.050 |
Why?
|
| Species Specificity | 1 | 2006 | 2411 | 0.050 |
Why?
|
| X-Rays | 1 | 2022 | 301 | 0.050 |
Why?
|
| Radiation Tolerance | 1 | 2024 | 477 | 0.050 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2021 | 3529 | 0.050 |
Why?
|
| bcl-X Protein | 1 | 2022 | 421 | 0.050 |
Why?
|
| Quinoxalines | 1 | 2022 | 287 | 0.050 |
Why?
|
| Light | 1 | 2006 | 1333 | 0.040 |
Why?
|
| Calcitonin | 1 | 2021 | 329 | 0.040 |
Why?
|
| Kidney Neoplasms | 1 | 2017 | 4272 | 0.040 |
Why?
|
| Anti-Bacterial Agents | 1 | 2018 | 7229 | 0.040 |
Why?
|
| Tissue Array Analysis | 1 | 2021 | 551 | 0.040 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2015 | 3985 | 0.040 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2022 | 375 | 0.040 |
Why?
|
| Digital Rectal Examination | 1 | 2019 | 40 | 0.040 |
Why?
|
| Watchful Waiting | 1 | 2023 | 502 | 0.040 |
Why?
|
| Treatment Outcome | 3 | 2023 | 63732 | 0.040 |
Why?
|
| Down-Regulation | 2 | 2017 | 2908 | 0.040 |
Why?
|
| Chlormadinone Acetate | 1 | 2017 | 2 | 0.040 |
Why?
|
| Cell Count | 1 | 2021 | 1833 | 0.040 |
Why?
|
| Risk Factors | 3 | 2021 | 72447 | 0.040 |
Why?
|
| Perineum | 1 | 2018 | 208 | 0.040 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2022 | 1137 | 0.040 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2021 | 613 | 0.030 |
Why?
|
| Postoperative Complications | 1 | 2018 | 15356 | 0.030 |
Why?
|
| Receptors, Androgen | 1 | 2022 | 1066 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2022 | 1408 | 0.030 |
Why?
|
| Kidney | 1 | 2010 | 6990 | 0.030 |
Why?
|
| Salvage Therapy | 1 | 2021 | 1267 | 0.030 |
Why?
|
| Plant Exudates | 1 | 2014 | 3 | 0.030 |
Why?
|
| Radiotherapy Dosage | 1 | 2021 | 2894 | 0.030 |
Why?
|
| Meteorological Concepts | 1 | 2014 | 29 | 0.030 |
Why?
|
| Plant Stems | 1 | 2014 | 18 | 0.030 |
Why?
|
| Arteries | 1 | 2019 | 1114 | 0.030 |
Why?
|
| Mice | 2 | 2021 | 80251 | 0.030 |
Why?
|
| Cambodia | 1 | 2014 | 184 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2017 | 10750 | 0.030 |
Why?
|
| Time Factors | 3 | 2017 | 39622 | 0.030 |
Why?
|
| Animals | 4 | 2021 | 166558 | 0.030 |
Why?
|
| International Cooperation | 1 | 2019 | 1417 | 0.030 |
Why?
|
| Cell Survival | 1 | 2021 | 5764 | 0.020 |
Why?
|
| Oviposition | 1 | 2011 | 23 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2017 | 1882 | 0.020 |
Why?
|
| Perioperative Care | 1 | 2018 | 999 | 0.020 |
Why?
|
| Diethylstilbestrol | 1 | 2010 | 90 | 0.020 |
Why?
|
| C-Reactive Protein | 1 | 2021 | 3752 | 0.020 |
Why?
|
| Lymph Node Excision | 1 | 2015 | 1278 | 0.020 |
Why?
|
| Urine | 1 | 2010 | 354 | 0.020 |
Why?
|
| Transfection | 1 | 2017 | 5789 | 0.020 |
Why?
|
| DNA | 1 | 2022 | 7208 | 0.020 |
Why?
|
| Quantitative Trait, Heritable | 1 | 2011 | 527 | 0.020 |
Why?
|
| RNA Interference | 1 | 2017 | 2845 | 0.020 |
Why?
|
| Catheters, Indwelling | 1 | 2010 | 425 | 0.020 |
Why?
|
| Lymphatic Metastasis | 1 | 2015 | 2919 | 0.020 |
Why?
|
| Biopsy | 1 | 2018 | 6734 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2016 | 6789 | 0.020 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2022 | 5613 | 0.020 |
Why?
|
| Fruit | 1 | 2011 | 1150 | 0.020 |
Why?
|
| Algorithms | 1 | 2006 | 13810 | 0.020 |
Why?
|
| Climate Change | 1 | 2011 | 470 | 0.020 |
Why?
|
| Adult | 5 | 2018 | 215192 | 0.010 |
Why?
|
| Lymph Nodes | 1 | 2015 | 3449 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2015 | 8378 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2019 | 10096 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2018 | 14124 | 0.010 |
Why?
|
| Prevalence | 1 | 2018 | 15312 | 0.010 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2010 | 6460 | 0.010 |
Why?
|
| Radiography | 1 | 2010 | 6950 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2021 | 23154 | 0.010 |
Why?
|
| Models, Biological | 1 | 2014 | 9455 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2018 | 38771 | 0.010 |
Why?
|
| Survival Rate | 1 | 2010 | 12645 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2010 | 12280 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2021 | 35797 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2015 | 20143 | 0.010 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2010 | 9193 | 0.010 |
Why?
|
| United States | 1 | 2019 | 70437 | 0.010 |
Why?
|
| Female | 1 | 2011 | 382450 | 0.000 |
Why?
|